are compound pharmacies stopping semaglutide Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s The End of Compounded Semaglutide:

GLP-1 has a plasma half-life of only 1.5-3 min with a high clearance indicating degradation in blood (52, 72)

Emerging medications like retatrutide may eventually surpass all current options, and the precise dosing comparisons between medications help clinicians optimize individual treatment plans

Recently Novo Nordisk announced the initiation of REDEFINE 4, a phase 3 trial comparing CagriSema 2.4 mg with Lillys Zepbound 15 mg evaluating weight loss after 72 weeks in 800 obese patients non-diabetic and is expected to be completed by October 2025 (NCT06131437)

Pushing medication too quickly forces tissue apart faster than it can naturally accommodate

As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development